Medroxyprogesterone Acetate Dosing for Endometrial Hyperplasia with Atypia in Fertility-Sparing Treatment
For endometrial hyperplasia with atypia (atypical hyperplasia/EIN) in patients desiring fertility, treat with medroxyprogesterone acetate (MPA) 400-600 mg daily for 6 months, then reassess with endometrial sampling.
Dosing Regimen
The ESMO-ESGO-ESTRO consensus guidelines 1 establish MPA 400-600 mg/day as the standard fertility-sparing treatment for atypical hyperplasia/endometrial intraepithelial neoplasia (AH/EIN). This high-dose continuous regimen differs fundamentally from the low-dose endometrial protection doses (2.5-5 mg) used in hormone replacement therapy 2.
Treatment Duration and Monitoring Algorithm:
- Initial treatment period: 6 months of continuous daily MPA 1
- Response assessment: Perform dilatation and curettage (D&C) with imaging at 6 months 1
- Interim monitoring: Endometrial sampling every 3-6 months during treatment 3, 4, 5
Response-Based Management:
If complete response at 6 months:
- Immediately encourage conception and refer to fertility clinic 1
- Pregnancy reduces recurrence risk 1
- If patient wishes to delay pregnancy, consider maintenance treatment for additional 6 months 1
If no response or persistent disease at 6 months:
- Continue MPA up to 12 months maximum 3, 5
- Perform pelvic MRI to exclude myometrial invasion before continuing 3, 5
- If still no response at 12 months, proceed to hysterectomy 3, 5
If progression at any point:
- Immediately proceed to standard surgical treatment (hysterectomy with staging) 1
Critical Pre-Treatment Requirements
Before initiating fertility-sparing therapy, all of the following criteria must be met 1:
- Histologic confirmation by specialist gynaecopathologist (preferably via D&C, not pipelle) 1
- Pelvic MRI to exclude myometrial invasion and adnexal involvement 1
- Grade 1 endometrioid histology only (not serous, clear cell, or carcinosarcoma) 3, 4, 5
- Referral to specialized center 1
- Patient counseling that this is non-standard treatment 1
- Patient willingness to accept close follow-up and future hysterectomy 1
Expected Outcomes and Recurrence
Response rates: Approximately 82% complete response for atypical hyperplasia 6, 7, though one study showed 81.8% 8
Recurrence risk: 50% of responders will experience recurrence 1, 7, typically within 7-36 months 6. This high recurrence rate necessitates:
Fertility outcomes: Live birth rate reaches 39% with assisted reproductive technology 1. The prospective multicenter trial 6 documented 12 pregnancies and 7 normal deliveries among responders.
Alternative Progestin Options
While MPA 400-600 mg/day is the guideline-recommended standard 1, alternatives include:
- Megestrol acetate: 160-320 mg/day 1
- Levonorgestrel-releasing IUD (LNG-IUS): With or without GnRH analogues 1, showing similar remission rates 1 and potentially higher regression rates in network meta-analyses 9, 10
The LNG-IUS may offer advantages with fewer systemic side effects, though the ESMO consensus maintains MPA as first-line with LNG-IUS as an alternative consideration 1.
Important Contraindications and Precautions
Absolute contraindications to MPA therapy include 3, 4, 5:
- Breast cancer
- Stroke or myocardial infarction history
- Pulmonary embolism or deep vein thrombosis
- Active smoking
Common side effects 6: Weight gain (grade 3 in 7% of patients), liver dysfunction (grade 3 in 3.6%), though no therapeutic deaths or irreversible toxicities were observed in the prospective trial.
Post-Treatment Surveillance
After achieving complete response:
- Endometrial sampling every 3-6 months 3, 4, 5
- Clinical examination every 6 months 1
- Immediate hysterectomy if recurrence occurs and fertility goals met 1
Critical pitfall: Endometrial cytology alone has only 61% sensitivity 11 and cannot replace D&C for therapeutic monitoring—always perform D&C for definitive assessment.